Suppr超能文献

术前慢性他汀类药物治疗在心脏移植受体中的作用:一项回顾性单中心队列研究。

The Role of Preoperative Chronic Statin Therapy in Heart Transplant Receipts-A Retrospective Single-Center Cohort Study.

机构信息

Emergency Institute for Cardiovascular Diseases and Transplantation, 540142 Targu Mures, Romania.

Department of Cell and Molecular Biology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 540142 Targu Mures, Romania.

出版信息

Int J Environ Res Public Health. 2023 Feb 16;20(4):3471. doi: 10.3390/ijerph20043471.

Abstract

BACKGROUND

Statin therapy has been proven to reduce the risk of cardiovascular events. The objective of our retrospective study was to investigate the relationship between preoperative chronic administration of statins to postoperative 2-month heart transplantation complications.

METHODS

A total number of 38 heart transplantation recipients from the Cardiovascular and Transplant Emergency Institute of Târgu Mureș between May 2014 and January 2021 were included in our study.

RESULTS

In logistic regression, we found a statistical significance between statin treatment and the presence of postoperative complications of any cause (OR: 0.06, 95% CI: 0.008-0.56; = 0.0128), simultaneously presenting an elevated risk for early-postoperative acute kidney injury (AKI). From the statin group, atorvastatin therapy had a higher risk of type 2 diabetes mellitus (T2DM) development (OR: 29.73, 95% CI: 1.19-741.76; = 0.0387) and AKI (OR: 29.73, 95% CI: 1.19-741.76; = 0.0387). C-reactive protein (CRP), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-c) represented risk factors, atorvastatin administration being independently associated with lower CRP values.

CONCLUSIONS

Chronic previous administration of statins represented a protective factor to the development of 2-month postoperative complications of any cause in heart transplant receipts.

摘要

背景

他汀类药物治疗已被证明可降低心血管事件的风险。我们回顾性研究的目的是调查术前长期服用他汀类药物与术后 2 个月心脏移植并发症之间的关系。

方法

我们纳入了 2014 年 5 月至 2021 年 1 月期间在特尔古穆列什心血管和移植急救研究所接受心脏移植的 38 名患者。

结果

在逻辑回归中,我们发现他汀类药物治疗与任何原因的术后并发症之间存在统计学意义(OR:0.06,95%CI:0.008-0.56; = 0.0128),同时也增加了术后早期急性肾损伤(AKI)的风险。在他汀类药物组中,阿托伐他汀治疗发生 2 型糖尿病(T2DM)的风险更高(OR:29.73,95%CI:1.19-741.76; = 0.0387)和 AKI(OR:29.73,95%CI:1.19-741.76; = 0.0387)。C 反应蛋白(CRP)、总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-c)是危险因素,阿托伐他汀治疗与 CRP 值降低独立相关。

结论

慢性服用他汀类药物是心脏移植受体术后 2 个月发生任何原因并发症的保护因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3533/9959876/760ede7c784c/ijerph-20-03471-g0A1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验